-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Hold on Biogen, Raises Price Target to $190

Benzinga·01/08/2026 16:44:35
Listen to the news
Truist Securities analyst Srikripa Devarakonda maintains Biogen (NASDAQ:BIIB) with a Hold and raises the price target from $142 to $190.